INACTIVE
Full-Time
Senior Research Associate
Cell Therapy Analytics
Posted on 2/7/2024
Develops Gene Writing genome engineering technology
Data & Analytics
Senior
Cambridge, MA, USA
Required Skills
Data Analysis
Requirements
- BS with 5+/MS with 3+ years of experience in Immunology, Immuno-oncology, cell and gene therapy or related field is required.
- Experience with research and/or manufacturing scale cell and tissue culture techniques with primary cells or established cell lines is required.
- Experience with cell therapy based unit operations, such as CliniMACS, CliniMACS Prodigy, Rotea, Cue, etc.
- Experience developing cell based, functional potency assays is a plus.
- Knowledge and experience with non-viral gene delivery and gene editing.
- Experience with flow cytometry is preferred.
- Experience in cell assay development and characterization is a plus.
- Experience with ELISA/MSD, qPCR, ddPCR, Incucyte, luciferase-based plate readouts and/or high speed cell sorting is a plus.
Responsibilities
- Support development and production of hematopoietic primary cell banks for use in Cell Therapy, Gene Writing platforms.
- Support characterization assays to inform the biology and process understanding of Gene Writing.
- Work collaboratively with process and analytics teams to execute developed analytics to inform in-process phenotypic and functional characterization of gene edited cells.
- Independently perform and screen new assays for analytical method selection.
- Assist in interpretation and troubleshooting of analytical assays in various platforms including, flow cytometry, ELISA/MSD, qPCR and ddPCR. Collect and interpret data, prepare experimental reports, and present findings to the IO Process team.
- Support the development of protocols, test methods, and analytical sampling plans.
Tessera Therapeutics is pioneering Gene Writing™, a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. They are focused on expanding possibilities in genetic medicine through tissue-targeted non-viral delivery technology, addressing major unmet medical needs with potentially curative and accessible therapies.
Company Stage
Series C
Total Funding
$581.7M
Headquarters
Somerville, Massachusetts
Founded
2018
Growth & Insights
Headcount
6 month growth
↑ 3%1 year growth
↑ 15%2 year growth
↑ 85%INACTIVE